Hepatitis C in the patient with human immunodeficiency virus infection

Journal of Hepatology

Volumn 29, Issue 6, 1998, Pages 1023-1030

  Spengler, Ulrich ^b   Rockstroh, Jürgen K ^a  

^a UNIVERSITY OF BONN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; INDINAVIR; NUCLEOSIDE DERIVATIVE; PROTEINASE INHIBITOR; RIBAVIRIN; SAQUINAVIR;

CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032403174     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80135-9     Document Type: Review

References (84)

1. 1. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26: 62S-65S.
2. 2. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. Case control study of a HIV-seroconversion in health care workers after percutanous exposure. N Engl J Med 1997; 337: 1485-90.
3. 3. Thomas DL, Zenilman JM, Alter HJ, Shih JW, Galai N, Carella AV, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore: an analysis of 309 sex partnerships. J Infect Dis 1995; 171: 768-75.
4. 4. Rockstroh JK, Ewig S, Bauer T, Luchters G, Oldenburg J, Bailly E, et al. Male to female transmission of HIV in a cohort of hemophiliacs - frequency, risk factors, and effect of sexual counselling. Infection 1995; 23: 29-32.
5. 5. Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997 (3 Suppl 1); 26: 665-705.
6. 6. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocola G, Caccamo ML, et al. Mother to infant transmission of hepatitis C virus. Lancet 1995; 345: 289-91.
7. 7. Nigro G, D'Orio F, Catania S, Badolato MC, Livadiotti S, Bernardi S, et al. Mother to infact transmission of coinfection by human immunodeficiency virus and hepatitis C virus: prevalence and clinical manifestations. Arch Virol 1997; 142: 453-7.
8. 8. Dore GJ, Kaldor JM, McCaughan GW. Systemic review of role of polymerase chain reaction in defining infectiousness among people infected with hepatitis C virus. Br Med J 1998; 315: 333-7.
9. 9. Chamot E, Hirschel B, Wintsch J, Robot CF, Gabriel V, Deglon JJ, et al. Loss of antibodies against hepatitis C virus in HIV seropositive intravenous drug users. AIDS 1990; 4: 1275-7.
10. 10. Chan TM, Lok AS, Chang IK, Chang RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology 1993; 17: 5-8.
11. 11. Lok AS, Chien D, Choo QL, Chan TM, Chiv EK, Cheng IK, et al. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunsuppressed patients. Hepatology 1993; 18: 497-502.
12. 12. Pol S, Legendre C, Saltiel C, Carnot F, Brechot C, Berthelot P, et al. Hepatitis C virus in kidney recipients: epidemiology and impact on renal transplantation. J Hepatol 1992; 15: 202-6.
13. 13. Ragni MV, Ndimbie OK, Rice EO, Bontempo FA, Nedja RS. The presence of hepatitis C virus (HCV) antibody in human immunodeficiency virus positive hemophiliac men undergoing HCV-seroreversion. Blood 1993; 82: 1010-5.
14. 14. Chambost H, Gerolami V, Halfon P, Thuret F, Michel G, Sicardi F, et al. Persistant hepatitis C virus RNA replication in hemophiliacs: role of coinfection with human immunodeficiency virus. Br J Haematol 1995; 91: 703-7.
15. 15. Allain JP, Dailey SH, Laurian Y, Vallari DS, Rafowicz A, Devare SG, et al. Evidence for persistant hepatitis C virus (HCV) infection in hemophiliacs. J Clin Invest 1991; 88: 1672-9.
16. 16. Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31: 2679-82.
17. 17. Cribier B, Rey D, Schmitt C, Lang JM, Kirn A, Stoll-Keller F. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131-6.
18. 18. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, et al. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996; 174: 690-5.
19. 19. Mazza C, Ravaggi A, Puoti M, Albertini A, Cariani E. Increased HCV titer and absence of selection of E2-hypervariable region (HVR1) in HCV-/HIV-coinfection. J Hepatol 1994; 21: S34.
20. 20. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Blood 1994; 84: 1020-3.
21. 21. Pol S, Thiers V, Nousbaum JB, Legendre Ch, Berthelot P, Krels H, et al. Changing distribution of HCV-genotypes in Europe in the last decades. J Hepatol 1994; 21: S13.
22. 22. Picchio GR, Nakatsuno M, Boggiano C, Sabbe R, Corti M, Daruich J, et al. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co-infection. J Med Virol 1997; 52: 219-25.
23. 23. Sabin CA, Telfer P, Phillips AN, Bhagani S, Lee CA. The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997; 175: 164-8.
24. 24. Garcia-Samaniego J, Soriano V, Castilla J, Bravo R, Moreno A, Carbo J, et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 1997; 92: 1130-4.
25. 25. Kanazawa Y, Hayashi N, Mita E, Li T, Hagawara H, Kasahara A, et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients. Hepatology 1994; 20: 1121-30.
26. 26. Cribier B, Schmitt C, Rey D, Uhl G, Lang JM, Vetter D, et al. HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype. Res Virol 1997; 148: 267-71.
27. 27. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-36.
28. 28. Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(suppl 1): 21S-28S.
29. 29. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 1997; 26(suppl 1): 34S-38S.
30. 30. Alberti A, Morsica G, Chemello L, Cavaletto D, Noventa F, Pontisso P, et al. Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV. Lancet 1992; 340: 697-8.
31. 31. Botarelli P, Brunetto MR, Minutello MA, Calvo P, Unutmat D, Werner AJ, et al. T-lymphocyte response to hepatitis C virus in different clinical courses of infection. Gastroenterology 1993; 104: S80.
32. 32. Lechmann M, Ihlenfeldt HG, Braunschweiger I, Giers G, Jung G, Matz B, et al. T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus-positive blood donors without viremia. Hepatology 1996; 24: 790-5.
33. 33. Telfer P, Sabin C, Devereux H, Scott F, Dusheiko G, Lee C. The progression of HCV-associated liver disease in a cohort of hemophiliac patients. Br J Haematol 1994; 87: 555-61.
34. 34. Sanchez-Quijano A, Andreu J, Gavilan F, Luque F, Abad MA, Soto B, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-53.
35. 35. Rockstroh JK, Spengler U, Sudhop T, Ewig S, Thersen A, Hammerstein U, et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91: 2563-8.
36. 36. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ, et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. J AIDS 1993; 6: 602-10.
37. 37. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengoechea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.
38. 38. Sanchez-Quijano A, Andreu J, Gavilan F, Lugne F, Abad MA, Soto B, et al. Influence of human immunodeficiency virus type 1 infection on the natural history of chronic parenteral-acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-53.
39. 39. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficency virus and hepatitis C virus infections. Clin Infect Dis 1996; 23: 1117-25.
40. 40. Pol S, Trinh Thi, Thiers V, Jaffredo F, Carnot F, Lamorthe B, et al. Chronic hepatitis of drug users: influence of HIV infection [abstract no 933]. Hepatology 1995; 22: 340A.
41. 41. Darby SC, Ewart DA, Giangrande PCF, Spooner RJ, Rizza CR, Dusheiko GM, et al. For the Haemophilia Centre Directors' Organisation. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997; 350: 1425-31.
42. 42. Dorrucci M, Pezzotti P, Philips AN, Lepri AC, Rezza G. Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995; 172: 1503-8.
43. 43. Quan CM, Krajden M, Grigoriew GA, Salit IE. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993; 17: 117-9.
44. 44. Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15: 101-9.
45. 45. Cohen P, Roulot D, Ferriere F, Nguyen QT, Lortholary O, Jarrousse B, et al. Prevalence of cryoglobulins and hepatitis C virus infection in HIV-infected patients. Clin Exp Rheumatol 1997; 15: 523-7.
46. 46. Bierhoff E, Fischer HP, Willsch E, Rockstroh J, Spengler U, Brackmann HH, et al. Liver histopathology in patients with concurrent hepatitis C and HIV-infection. Virchows Arch 1997; 430: 271-7.
47. 47. Ghany MG, Leissinger C, Lagier R, Sanchez-Pescador R, Lok AS. Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Dig Dis Sci 1996; 41: 1265-72.
48. 48. Bach N, Theise ND, Schaffner F. Hepatic histopathology in the acquired immunodeficiency syndrome. Semin Liver Dis 1992; 12: 205-12.
49. 49. Toyoda H, Fukuda Y, Koyama Y, Takamatsu J, Saito H, Hayakawa T. Effect of immunosuppression on composition of quasispecies population of hepatitis C virus in patients with chronic hepatitis C coinfected with human immunodeficiency virus. J Hepatol 1997; 26: 975-82.
50. 50. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kiaplowitz N, et al. Formulation and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-5.
51. 51. Cribier B, Schmitt C, Rey D, Lang JM, Kim A, Stoll-Keller F, et al. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Res Virol 1996; 147: 263-6.
52. 52. Romagnani S, Del Prete PG, Maggi E, Chilosi M, Caligaris-Cappro F, Pizzolo G, et al. CD30 and type 2 T helper (Th2) responses. J Leukoc Biol 1995; 57: 726-30.
53. 53. Romagnani S. Biology of human TH1 and TH2 cells. J Clin Immunol 1995; 15: 121-9.
54. 54. Davis GL, Balart LA, Schiff ER, Lindsay KL, Bodenheimer HC, Perillo RD, et al. Treatment of chronic hepatitis C with recombinant interferon-α. N Engl J Med 1990; 321: 1501-6.
55. 55. Lindsay L. Therapy of hepatitis C: overview. Hepatology 1997; 26(suppl 1): 71S-77S.
56. 56. Rockstroh JK, Spengler U, Sauerbruch T. Therapie der Virushepatitis bei HIV-Infizierten. DMW 1995; 120: 1705-8.
57. 57. Aguilar Y, Ryoce R, Antunez JM, Castano MA, Jimenez Onate F. Interferon treatment of chronic hepatitis C infection in HIV infected and high risk uninfected people in Malaga Spain [abstract no 3478]. In: Program and abstracts of the 8th International Conference on AIDS (Amsterdam). Amsterdam, CONGREX Holland By 1992; B163.
58. 58. Garcia-Samaniego J, Soriano V, Bravo R, Martinez-Odorozola P, Gonzales J, Castro A, et al. Efficacy and safety of alpha interferon therapy for chronic hepatitis C in HIV+ patients [abstract no 263]. Hepatology 1994; 20: 162A.
59. 59. Del Pozo MA, Arias JR, Garotte E, Pinilla J, Labarga P, Anton F, et al. A long term multicentric trial of recombinant interferon alpha 2b and zidovudine in HIV infected patients with chronic hepatitis C: response related factors [abstract no 296]. Hepatology 1994; 21: 170A.
60. 60. Venkataramani A, Roud R, Beaumont C, Lyche K. Interferon therapy in patients coinfected with hepatitis C (HCV) and human immunodeficiency virus (HIV). Hepatology 1997; 26: 313A.
61. 61. Cacciarelli A, Torres R, Mcintyre K, Turcheo F, Cairdie P. Safety and efficacy of interferon-α 2b in the treatment of hepatitis C infection in HIV-1 seropositive patients. Abstract of the 4th Congress on Retroviruses and Opportunistic Infections 1997; Washington, 677.
62. 62. DeSanctis GM, Errera G, Barbacini G, Leonetti G, Bergami N, Chircu LW. Long-term outcome of chronic hepatitis infection in HIV-+subjects treated with interferon. In: Program and Abstracts of the 9th International Conference on AIDS, Berlin, Germany, 1993: B19-1822.
63. 63. Marcellin P, Boyer N, Areias J, Erbinger S, Benhamou JP. Comparison of efficacy of α-interferon in former intravenous drug addicts with chronic hepatitis with or without HIV-infection. Gastroenterology 1994; 106: A938.
64. 64. Soriano V, Garcia-Samaniego J, Bravo R, et al. Interferon-α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 23: 585-91.
65. 65. Piliero PJ, Szebeny IS, Bartholome WC, Bartholomew WC, Bando C, Marini A, et al. Recombinant interferon therapy for chronic hepatitis C in patients with HIV. Abstracts of the 4th Conference on Retroviruses and Opportunistic Infections, Washington, 1997: 672.
66. 66. Mauss S, Klinker H, Ulmer A, Willers R, Weißbrich B, Albrecht H, et al. Response to treatment of chronic hepatitis C with interferon α in patients infected with HIV-1 is associated with higher CD4- cell count. Infection 1998; 26: 16-9.
67. 67. Marriot E, Navas S, del Romero I, Garcia S, Castillo I, Quiroga JA, et al. Treatment with combinant α-interferon of chronic hepatitis C in anti-HIV-positive patients. J Med Virol 1993; 40: 107-11.
68. 68. Soriano V, Garcia-Samaniego J, Bravo R, Castro A, Odriozolla PM, Gonzalez J, et al. Efficacy and safety of alpha-interferon treatment of chronic hepatitis C in HIV-infected patients. J Infection 1995; 31: 9-13.
69. 69. Vento S, Di Perri G, Cruciani M, Garofano T, Cancia E, Basseti D. Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection [letter]. Lancet 1993; 341: 958-9.
70. 70. Chemello L, Bonetti P, Cavaletto L, Talato F, Donadon V, Casani P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700-6.
71. 71. Hanley JP, Jarves LM, Andrew J, Dennis R, Hages PC, Piris J, et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs - influence of the viral load, genotype and liver pathology on response. Blood 1996; 87: 1704-9.
72. 72. Puoti M, Rossi S, Hammad I, et al. Effect of treatment with interferon-α 2b on liver disease and survival in subjects with HIV in chronic viral active hepatitis. Hepatology 1994; 20: 163A.
73. 73. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Wejland O. Randomized double-blind placebo-controlled trial of interferon-α 2b with an without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
74. 74. McCormick JB, Getchell JP, Mitchell SW, Hicks DR. Ribaverin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T-lymphocytes. Lancet 1984; 15: 1367-9.
75. 75. Fernandes-Larsson R, Patterson JL. Ribaverin is an inhibitor of human immunodeficiency virus reverse transkriptase. Molecular Pharmacol 1990; 38: 766-70.
76. 76. Connor E, Morrison S, Lane J, Oleshe J, Sonke RC, Connor J, et al. Safety, tolerance and pharmacokinetics of systemic ribaverin sodium with human immunodeficiency virus infection. Antimicrobiol Agents Chemother 1993; 37: 532-9.
77. 77. Roberts RB, Dickinson GM, Haseltine PN, Leedom JM, Mansell PW, Rodriguez S, et al. Multicenter clinical trial of oral ribaverin in HIV-infected patients with lymphadenopathy. J Acquir Immun Defic Syndr 1990; 3: 884-92.
78. 78. Vogt MW, Hartshorn KL, Furman PA, Chon TC, Fyfe JA, Coleman LA, et al. Ribaverin antagonizes the effect of azidothymidine of HIV-replication. Science 1987; 235: 1376-9.
79. 79. Bernier R, Tremblay M, Tsoukas C, Bergeron MG. Drug sensitivity of human immunodeficiency virus type 1 isolates after ribaverin therapy. J Infect Dis 1997; 175: 176-8.
80. 80. Centers for Disease Control and Prevention, Update. Trends in AIDS incidence. Morbidity, Mortality Weekly Report 1997; 46: 165-73.
81. 81. Carr A, Marriott D, Field A, Varsah E, Cooper DA. Treatment of HIV-1-associated microsporidosis and cryptosporidosis with combination antiretroviral therapy. Lancet 1998; 351: 256-61.
82. 82. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in an HIV-infected patient on protease inhibitor. Lancet 1997; 349: 996-7.
83. 83. Rutschmann OT, Negro F, Hirschel B, Hadengue A, Anwar D, Perrin LH. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J Infect Dis 1998; 177: 783-5.
84. 84. Rockstroh JK, Theisen A, Kaiser R, Sauerbruch T, Spengler U. Antiretroviral triple therapy decreases HIV-viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-/HCV-coinfected hemophiliacs. AIDS 1998; 12: 829-30.